Edwards Lifesciences Corp (EW), a biotechnology firm, has seen a number of fluctuations in its financial performance according to various updates. Its stock both underperformed and outperformed competitors in different instances. Despite some losses, there was also strong trading activity present. Recommendations varied, with Citigroup maintaining a 'Buy' recommendation while Stifel sticking to a 'Hold'. Over the past five years, investors in EW have enjoyed a decent return of 50%. Negative clinical trial results did affect the stock negatively in Q3, but positive news about Q4 and full-year 2023 have aided recovery. Edwards Lifesciences is also set to spin off its critical care unit in 2024. A promising surge of 21.8% YTD has been reported and forecasts predict growth in value. Some market analysts suggest that the current moment might be opportune for considering investment in EW. There's caution though, with potential intrinsic value being 17% below the share price. Still, institutional shareholders demonstrating confidence own a majority of 83% of the company. Notable activity includes Los Angeles Management LLC selling a large number of shares while Benjamin F. Edwards & Company Inc raised its stake in EW.
Edwards Lifesciences Corp EW News Analytics from Tue, 29 Aug 2023 07:00:00 GMT to Sat, 11 May 2024 22:54:30 GMT -
